ML24072A078

From kanterella
Jump to navigation Jump to search
Closed Meeting Notice Mar 18 2024 on Synovetin Oa
ML24072A078
Person / Time
Issue date: 03/18/2024
From: Spence S
NRC/NMSS/DMSST/MSEB
To:
Exubrion Therapeutics
References
Download: ML24072A078 (3)


Text

NON-

PUBLIC MEETING ANNOUNCEMENT

Title:

Closed Meeting with Exubrion Therapeutics Date(s) and Time(s): March 18, 2024, 11:30 AM to 12:20 PM ET Location:

Microsoft Teams Category:

This is a closed meeting. This meeting is closed to the public because proprietary design and use information will be discussed during the meeting.

Purpose:

The purpose of this meeting is to have discussions with Exubrion Therapeutics (Exubrion) regarding Exubrions Synovetin OA product, which is a tin-117m colloid for the treatment of osteoarthritis in canines.

Contact:

Sarah Spence 301-415-3697 sarah.spence@nrc.gov

Participants:

NRC Office of Nuclear Material Safety and Safeguards External Exubrion Therapeutics

NON-

PUBLIC MEETING AGENDA

Closed Meeting with Exubrion Therapeutics March 18, 2024, 11:30 AM to 12:20PM ET Microsoft Teams Time Topic Speaker 11:30 -

12:20 AM Introductions and opening remarks Requests for additional information regarding Synovetin OA Discussion NRC/Exubrion NRC NRC/Exubrion

The time of the meeting is local to the jurisdiction where the meeting is being held.

The NRC provides reasonable accommodation to individuals with disabilities where appropriate. If reasonable accommodation is needed to participate in this meeting, or if a meeting notice, transcript, or other information from this meeting is needed in another format (e.g., Braille, large print), please notify the NRC meeting contact.

Determinations on requests for reasonable accommodation will be made on a case-by-case basis.

ADAMS Accession Number: ML24XXXXXXX OFFICIAL RECORD COPY Link to meeting details:

Commission's Policy Statement on "Enhancing Public Participation in NRC Meetings" 86 Federal Register 14964, March 19, 2021 The policy statement may be found at https://www.govinfo.gov/content/pkg/FR-2021-03-19/pdf/2021-05787.pdf